|
Synonyms: IGE25 | olizumab | R03DX05 | RG-3648 | rhumab-E25 | Xolair®
omalizumab is an approved drug (FDA (2003), EMA (2005))
Compound class:
Antibody
Comment: Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Peptide sequence analysis reveals that omalizumab is clone e25 in patent US5994511 [3]. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖
View more information in the IUPHAR Pharmacology Education Project: omalizumab |
| References |
|
1. Arm JP, Bottoli I, Skerjanec A, Floch D, Groenewegen A, Maahs S, Owen CE, Jones I, Lowe PJ. (2014)
Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy, 44 (11): 1371-85. [PMID:25200415] |
|
2. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N. (2001)
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol, 108 (2): 184-90. [PMID:11496232] |
|
3. Lowman HB, Presta LG, Jardieu PM, Lowe J. (1999)
Anti-IgE antibodies and methods of improving polypeptides. Patent number: US5994511. Assignee: Genentech, Inc.. Priority date: 02/07/1997. Publication date: 30/11/1999. |
